PUBLIC COMPANY
save$BCAXBicara Therapeutics Inc.
$BCAX17.63-3.13%Boston, MA, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 21, 26option exerciseHyep Ivan · Chief Financial Officer9,200 sh
- Apr 21, 26option exerciseHyep Ivan · Chief Financial Officer9,200 sh
- Apr 20, 26option exerciseMazumdar Claire · Chief Executive Officer15,000 sh
- Apr 20, 26option exerciseMazumdar Claire · Chief Executive Officer15,000 sh
- Apr 16, 26option exerciseMazumdar Claire · Chief Executive Officer7,080 sh
- Apr 16, 26option exerciseMazumdar Claire · Chief Executive Officer8,226 sh
🐶 Hiring Signal
News
- Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board→ Some big changes are coming at Bicara Therapeutics, and it starts at the top. President and COO Ryan Cohlhepp will take over as CEO on Jan. 1, and Claire Mazumdar ...endpoints · 1mo ago
- Chutes & Ladders—Former Legend CEO lands at K2Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…fiercebiotech · 1mo ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that